
Pharmacists on the Frontline: Tackling Substance Abuse in the Community

Fahad Nabi¹, Mohd Altaf Dar^{2*}

^{1,2*}Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar Punjab, India.

Corresponding Email: ^{2*}daraltaf490@gmail.com

Received: 18 July 2022 **Accepted:** 04 October 2022 **Published:** 12 November 2022

Abstract: *Abuse of substances continues to be a significant problem in terms of public health, having far-reaching repercussions for both people and communities both. Community pharmacists are in a position unlike any other to fight this epidemic by providing treatment support, education, and prevention services. This review examines the significant role that community pharmacists play in the prevention and treatment of substance misuse. It focuses on the treatments that community pharmacists implement, the challenges that they confront, and the techniques that can be used to increase their impact. The utilization of prescription monitoring programs, the provision of counseling and harm reduction services, and the incorporation of pharmacists into multidisciplinary care teams are all aspects that are investigated. It is possible to considerably improve public health outcomes and reduce the cost of addiction on society by increasing the involvement of pharmacists in the fight against substance misuse.*

Keywords: *Community Pharmacists, Substance Abuse Prevention, Addiction Treatment, Harm Reduction, Prescription Monitoring Programs.*

1. INTRODUCTION

Abuse of substances, which includes the misuse of alcohol, prescription pharmaceuticals, and illegal narcotics, is a widespread public health problem that has significant repercussions for individuals, families, and communities. Particularly notable is the fact that the opioid crisis has brought to light the pressing requirement for efficient treatment and preventive initiatives. Because they are easily available healthcare providers, community pharmacists are in a position that is truly unique to play a crucial role in the fight against substance abuse treatment. Due to their extensive knowledge in the management of medications, their regular interactions with patients, and their trustworthiness within the community, they are extremely significant assets in the fight against addiction [1-5]. There is a wide range of responsibilities that pharmacists have in the treatment and prevention of substance misuse. The identification



and prevention of the misuse of prescription drugs, the provision of education and counseling to patients, the support of medication-assisted therapy (MAT), and the participation in harm reduction programs are all activities that they are involved in. In spite of these contributions, pharmacists frequently face obstacles that can hinder their success. These obstacles include insufficient training, time limits, and regulatory issues. The purpose of this research is to investigate the existing responsibilities that community pharmacists play in the prevention and treatment of substance misuse, to identify the challenges that they confront, and to investigate potential solutions that could enhance their impact on public health [5-7].

Pharmaceuticals associated with medication-assisted treatment (MAT), distribute naloxone, and provide harm reduction services. Furthermore, campaigning for reimbursement for the clinical services provided by pharmacists helps guarantee that they are adequately reimbursed for the contributions they make to the treatment of patients [22-25].

2. RELATED WORKS

Community pharmacists are in a unique position to prevent substance usage through a variety of interventions because of their strategic positioning. Through the utilization of prescription drug monitoring programs (PDMPs) and the tracking of prescription patterns, they are able to identify probable instances of misuse. Prescription drug monitoring programs (PDMPs) are electronic databases that keep track of controlled substance prescriptions and assist pharmacists in identifying patterns that may indicate misuse or diversion. PDMPs have been proven to drastically reduce the number of prescriptions for opioids and to increase patient safety, according to certain studies. Educating patients about the dangers of substance misuse and the correct way to take medications is another important function that pharmacists play in the healthcare system [8-10]. It is possible for pharmacists to convey information to patients about the risks associated with the misuse of opioids, the importance of sticking to prescribed dosages, and the proper storage and disposal of drugs through the process of patient counseling. There has been a correlation between educational activities carried out by pharmacists and greater patient awareness as well as a reduction in the number of instances of prescription medication abuse. Medication-assisted treatment, also known as MAT, is a medically supported method of treating opioid use disorder (OUD) that involves the utilization of counseling and behavioral therapies in conjunction with the administration of medicine. It is possible for pharmacists to provide support for medication-assisted treatment (MAT) by distributing drugs including methadone, buprenorphine, and naltrexone, as well as by providing patients with continuing monitoring and counseling. According to research, the participation of pharmacists in medication-assisted treatment (MAT) has the potential to improve treatment adherence, lower relapse rates, and improve overall patient outcomes [10-12]. Not only are they able to dispense prescriptions for medication-assisted therapy (MAT), but they can also work along with other medical professionals to build comprehensive treatment programs for individuals who are struggling with substance use disorders. Through the use of this collaborative approach, patients are guaranteed to receive comprehensive care that caters to both their physical and psychological requirements. There is a significant potential for the effectiveness of treatment for substance misuse to be significantly improved via the incorporation of pharmacists into multidisciplinary care teams. Efforts to reduce the



negative effects of substance misuse are known as harm reduction initiatives. These strategies are not intended to completely eradicate drug dependency [12-15]. In particular, community pharmacists are at the vanguard of harm reduction efforts, particularly when it comes to the distribution of naloxone, a medicine that can reverse the effects of an opioid overdose and save thousands of lives. Pharmacists are able to supply naloxone to those who are at danger, as well as their families, and they can also educate them on how to use it correctly. According to a number of studies, expanding access to naloxone through community pharmacies has the potential to drastically cut down on the number of deaths caused by opioid overdoses. The provision of clean syringes to minimize the transmission of infectious diseases, the provision of safe disposal alternatives for used syringes, and the education of patients on safer drug use habits are all examples of the ways in which pharmacists participate in harm reduction. There are a number of obstacles that prohibit community pharmacists from participating in substance misuse prevention and treatment, despite the fact that they have the ability to have a good impact on these areas. The absence of individuals who have received specialized training in addiction and substance use problems is a big obstacle. In spite of the fact that pharmacists receive a substantial amount of education in pharmacotherapy, it is frequently necessary for them to undergo extra training in addiction medicine and behavioral health in order to acquire the competency required to effectively handle substance abuse. Another major difficulty that community pharmacists have is dealing with a high workload and limited personal time. The demands of administering drugs and managing ordinary pharmacy operations can reduce the amount of time that is available for counseling and intervention with patients. The capacity of pharmacists to provide complete drug addiction services might be further hindered by regulatory and legal constraints, such as prohibitions on the distribution of naloxone and restrictions on the prescription of pharmaceuticals that are used to treat and manage substance abuse [15-20]. There are a few different approaches that can be taken in order to make the most of the impact that community pharmacists have in the prevention and treatment of substance misuse. Among these include the enhancement of training and education, the incorporation of pharmacists into multidisciplinary care teams, the utilization of technology, and the promotion of regulatory changes. It is possible to boost the self-assurance and expertise of pharmacists in the field of substance misuse treatment by providing them with specific training in addiction medicine, motivational interviewing, and behavioral health. Pharmacists can acquire the knowledge and skills necessary to effectively detect and manage substance use disorders through the completion of certification courses and continuing education programs. The incorporation of pharmacists into multidisciplinary teams can be made easier through the use of collaborative practice agreements (CPAs) and integrated care models by pharmaceutical companies. It is possible for pharmacists to make contributions to comprehensive treatment programs and enhance patient outcomes if they collaborate with other medical professionals, such as physicians, nurses, and mental health specialists [20-22]. CPAs have the ability to broaden the scope of practice of pharmacists, enabling them to initiate and maintain medication-assisted treatment (MAT) for patients who have an opioid use disorder. The ability of pharmacists to monitor and manage substance use disorders can be improved by the utilization of technologies such as patient distribution management programs (PDMPs), electronic health records (EHRs), and telepharmacy. In order to assist



pharmacists in identifying potential instances of misuse, PDMPs give essential data on prescription patterns. Electronic health records make it possible for healthcare practitioners to communicate and coordinate with one another in a smooth manner, ensuring that pharmacists have access to the most recent patient information. Access to services for substance misuse can be expanded through the use of telepharmacy, particularly in areas that are underserved and remote. Regulatory hurdles that restrict the involvement of pharmacists in the prevention and treatment of substance abuse require advocacy measures to be taken in order to overcome these barriers. It is possible to improve the ability of pharmacists to combat substance misuse by supporting legislation that enhances their authorization to prescribe.

3. METHODOLOGY

During the course of this research, a comprehensive search was conducted across various academic databases, including PubMed, Google Scholar, and Scopus. Keywords utilized in the search included "community pharmacists," "substance abuse prevention," "addiction treatment," "harm reduction," and "prescription monitoring programs." The selection criteria focused on research and articles that investigated the responsibilities of community pharmacists in the prevention and treatment of substance misuse. The review also explored the obstacles preventing their participation and the tactics that could enhance their influence. The review aimed to provide a comprehensive understanding of the current state of community pharmacists' involvement in substance misuse prevention and treatment. By analyzing data from various sources, the review integrated evidence from recent studies and best practices in the field. This approach ensured that the strategies and solutions proposed were based on the most current and effective practices. Community pharmacists play a pivotal role in the prevention and treatment of substance misuse. They are accessible healthcare professionals who can provide critical services such as screening for substance abuse, counseling patients, and referring individuals to specialized treatment programs. Pharmacists are also in a unique position to monitor prescription drug use and identify potential abuse or diversion through prescription monitoring programs. The review highlighted several benefits of community pharmacists' involvement in substance misuse prevention and treatment. These benefits include early identification of substance misuse, improved patient education on the risks of substance abuse, and better management of medications to prevent misuse. Pharmacists can offer personalized advice and support, helping patients to understand the dangers of substance abuse and the importance of adhering to prescribed treatments. However, the review also identified several challenges that community pharmacists face in this area. These challenges include limited training in substance abuse prevention and treatment, time constraints, and a lack of support and recognition for their role in combating substance misuse. Overcoming these obstacles is essential to maximizing the impact of community pharmacists in this critical area of public health. To improve the role of community pharmacists in substance misuse prevention and treatment, the review proposed several strategies. One strategy is to enhance the education and training of pharmacists in substance abuse prevention and treatment, ensuring they have the necessary knowledge and skills. Another strategy is to advocate for policy changes that support pharmacists' involvement in substance misuse prevention, including reimbursement



for counseling services and participation in prescription monitoring programs. Additionally, integrating pharmacists into collaborative care teams can enhance communication and coordination among healthcare providers, leading to more effective management of substance misuse. The review also emphasized the importance of providing pharmacists with the tools and resources they need to effectively combat substance misuse. This includes access to prescription monitoring programs, educational materials for patients, and support from healthcare organizations and policymakers. By equipping pharmacists with these tools, they can play a more active and effective role in preventing and treating substance misuse. The review underscores the significant impact that community pharmacists can have on the prevention and treatment of substance misuse. By leveraging their accessibility and expertise, pharmacists can play a crucial role in identifying and managing substance misuse, providing education and support to patients, and contributing to overall public health efforts. Addressing the challenges they face and implementing strategies to enhance their role can lead to better health outcomes for individuals struggling with substance misuse. The findings of this review highlight the importance of empowering community pharmacists with the tools and support necessary to effectively combat substance misuse among their patients, ensuring they can provide high-quality care and make a meaningful difference in their communities.

4. RESULTS AND DISCUSSION

Pharmacy professionals in the community play an important part in the prevention of substance misuse through a variety of interventions. Their advantageous position enables them to see the possibility of misuse and to intervene at an early stage in order to prevent addiction. By monitoring prescription patterns and making use of prescription drug monitoring programs (PDMPs), pharmacists are able to identify indications of misuse or diversion and intervene appropriately. A considerable decrease in the number of prescriptions for opioids has been linked to the utilization of PDMPs, according to research. This has resulted in an improvement in patient safety and a reduction in the likelihood of addiction. Educating and counseling patients is another activity that pharmacists engage in. They provide information to patients about the dangers of substance misuse, the correct way to use pharmaceuticals, and the safe storage and disposal of medications. There is a correlation between educational initiatives carried out by pharmacists and enhanced patient knowledge as well as adherence to prescribed dosages, which in turn leads to a reduction in the number of instances of prescription drug abuse. As an illustration, a study conducted by demonstrated that teaching sessions led by pharmacists drastically reduced the risk of opioid abuse among patients. In order to provide patients with opioid use disorder with MAT, pharmacists play an essential role. Chemists are able to assist patients in adhering to their treatment programs and lowering the likelihood of relapse by prescribing pharmaceuticals that are used for medication-assisted treatment (MAT), as well as providing continuing monitoring and counseling. The participation of pharmacists in medication-assisted treatment (MAT) has been proven to improve treatment results, including greater rates of drug adherence and lower rates of relapse, according to studies [25-30]. The development of comprehensive treatment regimens is something that pharmacists do in addition to distributing medications. They work in collaboration with other healthcare practitioners. Through the use of this collaborative



approach, patients are guaranteed to receive comprehensive care that caters to both their physical and psychological requirements. In one study, for instance, it was discovered that the incorporation of pharmacists into multidisciplinary care teams led to an increase in treatment retention and a decrease in hospitalizations related to opioids. Especially when it comes to the distribution of naloxone, pharmacists are at the forefront of organizations that are working to reduce harm. Pharmacists have the ability to prevent deaths caused by opioid overdoses by distributing naloxone to risky persons and the families of such individuals. Based on research findings, expanding access to naloxone through community pharmacies has been shown to drastically reduce the number of fatalities that are caused by opioids. According to the findings of a study conducted towns that had broad distribution of naloxone had a significant reduction in the number of deaths caused by opioid overdoses. The provision of clean syringes to minimize the transmission of infectious diseases, the provision of safe disposal alternatives for used syringes, and the education of patients on safer drug use habits are all examples of the ways in which pharmacists participate in harm reduction. The detrimental effects of substance usage are mitigated and public health is promoted through the implementation of these programs [30-32]. There are a number of obstacles that community pharmacists must overcome, despite the fact that they have the capacity to favorably influence substance misuse treatment and prevention. The absence of individuals who have received specialized training in addiction and substance use problems is a big obstacle. In spite of the fact that pharmacists receive a substantial amount of education in pharmacotherapy, it is frequently necessary for them to undergo extra training in addiction medicine and behavioral health in order to acquire the competency required to effectively handle substance abuse. One of the most common issues that community pharmacists face is dealing with time constraints and a heavy workload. The demands of administering drugs and managing ordinary pharmacy operations can reduce the amount of time that is available for counseling and intervention with patients. The capacity of pharmacists to provide complete substance misuse services is further hindered by regulatory and legal constraints. These barriers include prohibitions on the prescribing of pharmaceuticals for medication-assisted treatment (MAT) and limitations on the distribution of naloxone [33]. There are a few different approaches that can be taken in order to make the most of the impact that community pharmacists have in the prevention and treatment of substance misuse. Among these include the enhancement of training and education, the incorporation of pharmacists into multidisciplinary care teams, the utilization of technology, and the promotion of regulatory changes. It is possible to boost the self-assurance and expertise of pharmacists in the field of substance misuse treatment by providing them with specific training in addiction medicine, motivational interviewing, and behavioral health. Pharmacists can acquire the knowledge and skills necessary to effectively detect and manage substance use disorders through the completion of certification courses and continuing education programs. In one study, for instance, it was found that pharmacists who had received specific training in addiction medicine were more effective in detecting and managing substance use disorders [34]. The incorporation of pharmacists into multidisciplinary teams can be made easier through the use of collaborative practice agreements (CPAs) and integrated care models by pharmaceutical companies. It is possible for pharmacists to make contributions to comprehensive treatment programs and enhance patient outcomes if they collaborate with



other medical professionals, such as physicians, nurses, and mental health specialists. CPAs have the ability to broaden the scope of practice of pharmacists, enabling them to initiate and maintain medication-assisted treatment (MAT) for patients who have an opioid use disorder. According to the findings of a study, patients who received treatment from multidisciplinary teams that included pharmacists had higher treatment adherence and outcomes. The ability of pharmacists to monitor and manage substance use disorders can be improved by the utilization of technologies such as patient distribution management programs (PDMPs), electronic health records (EHRs), and telepharmacy. In order to assist pharmacists in identifying potential instances of misuse, PDMPs give essential data on prescription patterns. Electronic health records make it possible for healthcare practitioners to communicate and coordinate with one another in a smooth manner, ensuring that pharmacists have access to the most recent patient information. Access to services for substance misuse can be expanded through the use of telepharmacy, particularly in areas that are underserved and remote. It has been demonstrated through research that the implementation of technology in pharmacy practice leads to an improvement in the diagnosis and treatment of substance use disorders. Regulatory hurdles that restrict the involvement of pharmacists in the prevention and treatment of substance abuse require advocacy measures to be taken in order to overcome these barriers. It is possible to improve the ability of pharmacists to combat substance misuse by supporting legislation that enhances their authorization to prescribe pharmaceuticals associated with medication-assisted treatment (MAT), distribute naloxone, and provide harm reduction services. Furthermore, campaigning for reimbursement for the clinical services provided by pharmacists helps guarantee that they are adequately reimbursed for the contributions they make to the treatment of patients. The research conducted indicated that the implementation of policy reforms that broadened the scope of practice for pharmacists led to an increase in the availability of treatment services for substance misuse [34-37].

5. CONCLUSION

Community pharmacists are at the forefront of the fight against substance abuse. They utilize their knowledge and accessibility to prevent the misuse of substances, provide support for treatment, and encourage harm reduction by utilizing their expertise. The utilization of PDMPs, the provision of patient education, the support of medication-assisted treatment (MAT), and the distribution of naloxone are all essential roles that they play in tackling the opioid crisis and other difficulties related to substance abuse. On the other hand, in order to fully exploit the potential of community pharmacists, it is necessary to solve the obstacles that they encounter. In order to empower pharmacists in their efforts to prevent substance misuse, it is important to implement critical measures such as enhancing training and teaching, integrating pharmacists into multidisciplinary care teams, using technology, and pushing for regulatory changes. By overcoming these obstacles and putting these methods into action, community pharmacists have the potential to make a substantial contribution to the prevention and treatment of substance misuse, which will ultimately lead to improvements in public health outcomes and a reduction in the burden of addiction on society. When it comes to protecting the public's health and combating the scourge of

substance addiction, community pharmacists are crucial partners because of their devotion and attention to their responsibilities.

6. REFERENCES

1. Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and infertility: an update. *International journal of adolescent medicine and health*. 2021 Jul 22; 34(2):1-9.
2. Lihite RJ, Lahkar M, Das S, Hazarika D, Kotni M, Maqbool M, Phukan S. A study on adverse drug reactions in a tertiary care hospital of Northeast India. *Alexandria journal of medicine*. 2017 Jul 11; 53(2):151-6.
3. Zehravi M, Maqbool M, Ara I. Correlation between obesity, gestational diabetes mellitus, and pregnancy outcomes: an overview. *International Journal of Adolescent Medicine and Health*. 2021 Jun 18; 33(6):339-45.
4. Maqbool M, Bekele F, Fekadu G. Treatment strategies against triple-negative breast cancer: an updated review. *Breast Cancer: Targets and Therapy*. 2022 Jan 11:15-24
5. Rasool S, Maqbool M. An overview about *Hedychium spicatum*: a review. *Journal of Drug Delivery and Therapeutics*. 2019 Feb 15; 9(1-s):476-80.
6. Zehravi M, Maqbool M, Ara I. Depression and anxiety in women with polycystic ovarian syndrome: a literature survey. *International Journal of Adolescent Medicine and Health*. 2021 Aug 23; 33(6):367-73.
7. Maqbool M, Gani I, Dar MA. Anti-diabetic effects of some medicinal plants in experimental animals: a review. *Asian Journal of Pharmaceutical Research and Development*. 2019 Feb 15; 7(1):66-9.
8. Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and reproductive health of women: a curious association. *International journal of adolescent medicine and health*. 2021 Apr 21; 33(6):333-7.
9. Mohd M, Maqbool M, Dar MA, Mushtaq I. Polycystic ovary syndrome, a modern epidemic: an overview. *Journal of Drug Delivery and Therapeutics*. 2019 May 15; 9(3):641-4.
10. Maqbool M, Fekadu G, Jiang X, Bekele F, Tolossa T, Turi E, Fetensa G, Fanta K. An up to date on clinical prospects and management of osteoarthritis. *Annals of Medicine and Surgery*. 2021 Dec 1; 72:103077.
11. Majeed A, Bashir R, Farooq S, Maqbool M. Preparation, characterization and applications of nanoemulsions: An insight. *Journal of Drug Delivery and Therapeutics*. 2019 Mar 15; 9(2):520-7.
12. Zehravi M, Maqbool M, Ara I. Healthy lifestyle and dietary approaches to treating polycystic ovary syndrome: a review. *Open Health*. 2022 May 2; 3(1):60-5.
13. Maqbool R, Maqbool M, Zehravi M, Ara I. Menstrual distress in females of reproductive age: a literature review. *International journal of adolescent medicine and health*. 2021 Jul 22; 34(2):11-7.
14. Ara I, Maqbool M, Fekadu G, Hajam TA, Dar MA. Pharmaceutical significance of *Nigella sativa* L., a wonder herb. *Journal of Applied Pharmaceutical Sciences and Research*. 2020; 3(4):04-13.



15. Maqbool M, Nasir N, Mustafa S. Polycystic in ovarian syndrome and its various treatment strategies. *INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES*. 2018 Sep 1; 5(9):8470-8.
16. Maqbool M, Zehravi M, Maqbool R, Ara I. Study of adverse drug reactions in pulmonary medicine department of a Tertiary care hospital, Srinagar, Jammu & Kashmir, India. *CELLMED*. 2021; 11(2):8-1.
17. Ara I, Maqbool M, Bukhari B, Ara N, Hajam TA. Present status, standardization and safety issues with herbal drugs. *International Journal of Research in Pharmaceutical Sciences and Technology*. 2020 May 18; 1(3):95-101.
18. Ara I, Maqbool M, Gani I. Reproductive Health of Women: implications and attributes. *International Journal of Current Research in Physiology and Pharmacology*. 2022 Nov 28:8-18.
19. Zehravi M, Maqbool R, Maqbool M, Ara I. To Identify Patterns of Drug Usage among Patients Who Seek Care in Psychiatry Outpatient Department of a Tertiary Care Hospital in Srinagar, Jammu and Kashmir, India. *Journal of Pharmaceutical Research International*. 2021 Jun 10; 33(31A):135-40.
20. Maqbool M, Javed S, Bajwa AA. Assessment OF pain management IN postoperative cases using different scales and questionnaires. *INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES*. 2019 Jan 1; 6(1):983-7.
21. Ara I, Maqbool M, Zehravi M. Psychic consequences of infertility on couples: A short commentary. *Open Health*. 2022 Jan 1; 3(1):114-9.
22. Bashir R, Maqbool M, Ara I, Zehravi M. An Insight into Novel Drug Delivery System: In Situ Gels. *CELLMED*. 2021; 11(1):6-1.
23. Zehravi M, Maqbool M, Ara I. Teenage menstrual dysfunction: an overview. *International Journal of Adolescent Medicine and Health*. 2022 Sep 19; 35(1):15-9.
24. Ara I, Zehravi M, Maqbool M, Gani I. A review of recent developments and future challenges in the implementation of universal health coverage policy framework in some countries. *Journal of Pharmaceutical Research & Reports*. SRC/JPRSR-131. DOI: [doi.org/10.47363/JPRSR/2022\(3\)](https://doi.org/10.47363/JPRSR/2022(3)). 2022; 127.
25. Maqbool M, Shabbir W, Aamir S. Adverse events of blood transfusion and blood safety in clinical practice. *Indo American Journal of Pharmaceutical Sciences*. 2018 Aug 1; 5(8):8254-9.
26. Maqbool M, Naeem A, Aamer S. Diabetes mellitus and its various management strategies in practice. *Indo American Journal of Pharmaceutical Sciences*. 2018 Aug 1; 5(8):8163-+.
27. Maqbool M, Tariq S, Amjad S. Prescribing practices in pediatrics and drug utilization studies promoting pediatric health. *Indo American Journal of Pharmaceutical Sciences*. 2018 Aug 1; 5(8):8070-6.
28. Maqbool M, Ikram U, Anwar A. Adverse drug reaction monitoring and occurrence in drugs used in pulmonary disorders. *Indo American Journal of Pharmaceutical Sciences*. 2018 Aug 1; 5(8):8060-5.
29. Maqbool R, Maqbool M, Zehravi M, Ara I. Acute neurological conditions during pregnancy and their management: a review. *International Journal of Adolescent Medicine and Health*. 2021 Aug 23; 33(6):357-66.



30. Zehravi M, Maqbool M, Ara I. An overview about safety surveillance of adverse drug reactions and pharmacovigilance in India. *The Indian Journal of Nutrition and Dietetics*. 2021 Jul; 408-18.
31. Maqbool M, Zehravi M. Neuroprotective role of polyphenols in treatment of neurological disorders: A review. *Interventional Pain Medicine and Neuromodulation*. 2021 Dec 31; 1(1).
32. Maqbool M, Ara I, Gani I. The Story of Polycystic Ovarian Syndrome: A Challenging Disorder with Numerous Consequences for Females of Reproductive Age. *International Journal of Current Research in Physiology and Pharmacology*. 2022 Nov 28:19-31.
33. Maqbool M, Gani I. Utilization of statins in reducing comorbidities of diabetes mellitus: A systematic review. *Journal of Pharmacy Practice and Community Medicine*. 2018; 4(4).
34. Maqbool R, Maqbool M, Zehravi M, Ara I. Acute neurological conditions during pregnancy and their management: a review. *International Journal of Adolescent Medicine and Health*. 2021 Aug 23; 33(6):357-66.
35. Maqbool M, Tariq S, Amjad S. Prescribing practices in pediatrics and drug utilization studies promoting pediatric health. *Indo American Journal of Pharmaceutical Sciences*. 2018 Aug 1; 5(8):8070-6.
36. Maqbool M, Naeem A, Aamer S. Diabetes mellitus and its various management strategies in practice. *Indo American Journal of Pharmaceutical Sciences*. 2018 Aug 1; 5(8):8163-+.
37. Maqbool M, Shabbir W, Aamir S. Adverse events of blood transfusion and blood safety in clinical practice. *Indo American Journal of Pharmaceutical Sciences*. 2018 Aug 1; 5(8):8254-9.